Cargando…
Appropriateness and Economic Analysis of Conventional Circulating Biomarkers Assessment in Early Breast Cancer: A Real-World Experience from the E.Pic.A Study
The risk of relapse for early breast cancer (BC) patients persists even after decades and to date, no specific and sensitive effective circulating biomarker for recurrence prediction has been identified yet. The international guidelines do not recommend the assessment of the serum tumor markers CEA...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870402/ https://www.ncbi.nlm.nih.gov/pubmed/35200539 http://dx.doi.org/10.3390/curroncol29020039 |
_version_ | 1784656734586929152 |
---|---|
author | Maltoni, Roberta Balzi, William Rossi, Tania Fabbri, Francesco Bravaccini, Sara Montella, Maria Teresa Massa, Ilaria Bertoni, Lucia Falcini, Fabio Altini, Mattia |
author_facet | Maltoni, Roberta Balzi, William Rossi, Tania Fabbri, Francesco Bravaccini, Sara Montella, Maria Teresa Massa, Ilaria Bertoni, Lucia Falcini, Fabio Altini, Mattia |
author_sort | Maltoni, Roberta |
collection | PubMed |
description | The risk of relapse for early breast cancer (BC) patients persists even after decades and to date, no specific and sensitive effective circulating biomarker for recurrence prediction has been identified yet. The international guidelines do not recommend the assessment of the serum tumor markers CEA and CA15-3 in the follow-up of asymptomatic early BC patients. In our institute, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, as part of the E.Pic.A study, which was designed to assess the economic appropriateness of integrated care pathways in early BC, the use of CEA and CA15-3 as circulating tumor biomarkers in early BC patients was evaluated in 1502 patients one year after surgery, from 2015 to 2018, with an overall expense of EUR 51,764. A total of EUR 47,780 (92%) was used for execution of circulating tumor markers in early BC patients with stage 0, I and II tumors, neglecting the current guidelines and considered inappropriate by our professional board. We found that no patients with stage I BC experienced relapse in the 365 days after surgery, and in any case examination of the circulating markers CEA and CA15-3 was considered crucial for diagnosis of relapse. Our findings suggest that this inadequacy is a low-value area, supporting the reallocation of economic resources for interventions of a higher value for patients. |
format | Online Article Text |
id | pubmed-8870402 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88704022022-02-25 Appropriateness and Economic Analysis of Conventional Circulating Biomarkers Assessment in Early Breast Cancer: A Real-World Experience from the E.Pic.A Study Maltoni, Roberta Balzi, William Rossi, Tania Fabbri, Francesco Bravaccini, Sara Montella, Maria Teresa Massa, Ilaria Bertoni, Lucia Falcini, Fabio Altini, Mattia Curr Oncol Communication The risk of relapse for early breast cancer (BC) patients persists even after decades and to date, no specific and sensitive effective circulating biomarker for recurrence prediction has been identified yet. The international guidelines do not recommend the assessment of the serum tumor markers CEA and CA15-3 in the follow-up of asymptomatic early BC patients. In our institute, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, as part of the E.Pic.A study, which was designed to assess the economic appropriateness of integrated care pathways in early BC, the use of CEA and CA15-3 as circulating tumor biomarkers in early BC patients was evaluated in 1502 patients one year after surgery, from 2015 to 2018, with an overall expense of EUR 51,764. A total of EUR 47,780 (92%) was used for execution of circulating tumor markers in early BC patients with stage 0, I and II tumors, neglecting the current guidelines and considered inappropriate by our professional board. We found that no patients with stage I BC experienced relapse in the 365 days after surgery, and in any case examination of the circulating markers CEA and CA15-3 was considered crucial for diagnosis of relapse. Our findings suggest that this inadequacy is a low-value area, supporting the reallocation of economic resources for interventions of a higher value for patients. MDPI 2022-01-18 /pmc/articles/PMC8870402/ /pubmed/35200539 http://dx.doi.org/10.3390/curroncol29020039 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Maltoni, Roberta Balzi, William Rossi, Tania Fabbri, Francesco Bravaccini, Sara Montella, Maria Teresa Massa, Ilaria Bertoni, Lucia Falcini, Fabio Altini, Mattia Appropriateness and Economic Analysis of Conventional Circulating Biomarkers Assessment in Early Breast Cancer: A Real-World Experience from the E.Pic.A Study |
title | Appropriateness and Economic Analysis of Conventional Circulating Biomarkers Assessment in Early Breast Cancer: A Real-World Experience from the E.Pic.A Study |
title_full | Appropriateness and Economic Analysis of Conventional Circulating Biomarkers Assessment in Early Breast Cancer: A Real-World Experience from the E.Pic.A Study |
title_fullStr | Appropriateness and Economic Analysis of Conventional Circulating Biomarkers Assessment in Early Breast Cancer: A Real-World Experience from the E.Pic.A Study |
title_full_unstemmed | Appropriateness and Economic Analysis of Conventional Circulating Biomarkers Assessment in Early Breast Cancer: A Real-World Experience from the E.Pic.A Study |
title_short | Appropriateness and Economic Analysis of Conventional Circulating Biomarkers Assessment in Early Breast Cancer: A Real-World Experience from the E.Pic.A Study |
title_sort | appropriateness and economic analysis of conventional circulating biomarkers assessment in early breast cancer: a real-world experience from the e.pic.a study |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870402/ https://www.ncbi.nlm.nih.gov/pubmed/35200539 http://dx.doi.org/10.3390/curroncol29020039 |
work_keys_str_mv | AT maltoniroberta appropriatenessandeconomicanalysisofconventionalcirculatingbiomarkersassessmentinearlybreastcancerarealworldexperiencefromtheepicastudy AT balziwilliam appropriatenessandeconomicanalysisofconventionalcirculatingbiomarkersassessmentinearlybreastcancerarealworldexperiencefromtheepicastudy AT rossitania appropriatenessandeconomicanalysisofconventionalcirculatingbiomarkersassessmentinearlybreastcancerarealworldexperiencefromtheepicastudy AT fabbrifrancesco appropriatenessandeconomicanalysisofconventionalcirculatingbiomarkersassessmentinearlybreastcancerarealworldexperiencefromtheepicastudy AT bravaccinisara appropriatenessandeconomicanalysisofconventionalcirculatingbiomarkersassessmentinearlybreastcancerarealworldexperiencefromtheepicastudy AT montellamariateresa appropriatenessandeconomicanalysisofconventionalcirculatingbiomarkersassessmentinearlybreastcancerarealworldexperiencefromtheepicastudy AT massailaria appropriatenessandeconomicanalysisofconventionalcirculatingbiomarkersassessmentinearlybreastcancerarealworldexperiencefromtheepicastudy AT bertonilucia appropriatenessandeconomicanalysisofconventionalcirculatingbiomarkersassessmentinearlybreastcancerarealworldexperiencefromtheepicastudy AT falcinifabio appropriatenessandeconomicanalysisofconventionalcirculatingbiomarkersassessmentinearlybreastcancerarealworldexperiencefromtheepicastudy AT altinimattia appropriatenessandeconomicanalysisofconventionalcirculatingbiomarkersassessmentinearlybreastcancerarealworldexperiencefromtheepicastudy |